Full
Outline
To observe the efficacy and mechanism of Zhibitai Capsules（脂必泰胶囊）in the treatment of patients with non-alcoholic fatty liver disease and chronic hepatitis B.
A random number grouping method was used to divide 100 patients with non-alcoholic fatty liver disease and hepatitis B who were hospitalized in the hospital from January 1，2022 to April 30，2023，into an observation group and a control group，with 50 patients in each group. The control group received tenofovir fumarate 25 mg once a day. Fifty cases in the observation group were given 0.24 g of Zhibitai Capsule twice a day for 2 months，during which both groups were given routine symptomatic treatment of western medicine. The liver function［alanine aminotransferase（ALT），asparagus cochinchinensis aminotransferase（AST），glutamyltransferase（γ-GT）］，blood lipids［total cholesterol（TC），triglycerides（TG），high-density lipoprotein（HDL-C），low-density lipoprotein（LDL-C）］，renal function［blood urea nitrogen（BUN），creatinine（Cr）］，HBV-DNA amount and changes in TCM symptom scores of the two groups were compared before and after treatment.
The trial has concluded with 10 ineffective patients in the control group and 3 ineffective patients in the observation group. The total effective rate of the observation group was 94%（47/50），which was higher than 80%（40/50）of the control group. Compared with those before treatment，the liver and kidney function，blood lipids and traditional Chinese medicine syndrome scores of HBV-DNA in both groups improved compared to those before treatment. The improvement of ALT，AST andγ-GT of the observation group was better than that of the control group（P<0.05）. The reduction degree of TC，TG and LDL-C was higher than that of the control group，and the improvement degree of HDL-Cwas better（P<0.05）. The TCM syndrome score significantly improved（P<0.05）.
Zhibitai Capsules can effectively improve the blood lipid level，liver and kidney functions，assist in inhibiting the replication of HBV virus，delay the progression of the disease，and has a high factor of safety，which can provide an effective reference for the development of clinical treatment plans for the disease.
44
19
| 科 Family | 属数 Number of genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) | 属 Genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) |
|---|---|---|---|---|---|---|
| 鹅膏菌科Amanitaceae | 2 | 11 | 5.26 | 鹅膏菌属 Amanita | 10 | 4.78 |
| 小菇科 Mycenaceae | 2 | 12 | 5.74 | 丝盖伞属 Inocybe | 5 | 2.39 |
| 多孔菌科 Polyporaceae | 8 | 14 | 6.70 | 蜡蘑属 Laccaria | 5 | 2.39 |
| 红菇科 Russulaceae | 3 | 23 | 11.00 | 小皮伞属 Marasmius | 6 | 2.87 |
| 小菇属 Mycena | 11 | 5.26 | ||||
| 光柄菇属 Pluteus | 5 | 2.39 | ||||
| 红菇属 Russula | 17 | 8.13 | ||||
| 栓菌属 Trametes | 5 | 2.39 |
关闭全屏
No. 86 Xueyuan South Road, Haidian District, Beijing
010-62662699(Operation and Technical Support)
qkjq@cast.org.cn
Copyright © 2025 China Association for Science and Technology. All rights reserved. For all open access content, the relevant licensing terms apply.
Sponsored by the Office of the Leading Group for Cybersecurity and Informatization of CAST, and supported by Science and Technology Review Publishing House
